Skip to content

What is hypogonadism? The low testosterone definition most men and many doctors get wrong

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Oct 19, 2026 · 14 min read

Listen to this article as a podcast episode

April 11, 2026 · 19:36

Low testosterone, clinically called male hypogonadism, is a syndrome defined by persistent symptoms plus biochemical evidence of testosterone deficiency confirmed on accurate morning testing. A lab number alone is not a diagnosis, and symptoms alone are not enough either. That distinction explains why some men are overtreated by number only clinics and others are undertreated when a “normal” range is used to dismiss clear testosterone deficiency.

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • Male hypogonadism requires persistent symptoms plus biochemical evidence of low testosterone. Neither one is enough on its own.[1] [2] [3]
  • Under the AUA guideline, total testosterone below 300 ng/dL supports the diagnosis, but a man at 320 ng/dL can still have testosterone deficiency if symptoms persist and free testosterone is low.[1] [4]
  • Testosterone should be measured in the morning, ideally between 07:00 and 11:00, because levels peak early in the day, particularly in younger men, and can fall with poor sleep, stress, and acute illness.[2] [3]
  • Only about 2% of circulating testosterone is free. About 44% is bound to SHBG and about half is loosely bound to albumin, which is why total testosterone can look “normal” while free testosterone is low.[5] [4]
  • LH and FSH must be measured with testosterone. High LH plus low testosterone suggests primary hypogonadism, while low or normal LH plus low testosterone suggests secondary hypogonadism.[2] [3] Because the testes are intact in secondary hypogonadism, treatment that restores the brain’s signal, such as enclomiphene, may be an option instead of lifelong testosterone replacement.

What low testosterone actually means

Male hypogonadism is a clinical syndrome defined by persistent symptoms plus biochemical evidence of testosterone deficiency, not by a single lab result alone.[2] [6] [3]

Hypogonadism means the testes are not producing enough testosterone for normal male function. Symptoms make the deficiency clinically meaningful, and accurate labs confirm that testosterone is truly low.

According to the Endocrine Society guideline, a diagnosis should be made only in men who have symptoms or signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone measured with an accurate assay.[2] The 2025 European Association of Urology guideline likewise describes late onset hypogonadism as low circulating testosterone combined with specific symptoms.[3] Both call for confirmation on repeat morning testing, because a temporary dip after illness, sleep loss, or acute stress does not equal true testosterone deficiency.[2] [6]

Why symptoms and labs both matter

A low number without symptoms is not enough, because treating a laboratory value that is not causing a clinical syndrome exposes a man to unnecessary medicalization. Symptoms without lab confirmation are also not enough, because fatigue, low mood, reduced exercise tolerance, and sexual symptoms can have many causes beyond low testosterone.[2]

This dual requirement is where two common errors happen. Some direct to consumer clinics treat the number alone. Some conventional practices dismiss the patient because the number sits inside a broad reference range. Both approaches miss the actual definition of male hypogonadism, which is a pattern of symptoms plus confirmed biochemical testosterone deficiency.

A 2010 New England Journal of Medicine analysis of the European Male Ageing Study found that late onset hypogonadism emerged most clearly when low testosterone coexisted with three sexual symptoms: reduced libido, erectile dysfunction, and fewer morning erections.[7] Other symptoms still matter, but sexual symptoms add diagnostic specificity.

Commonly reported symptoms and signs include reduced libido, erectile dysfunction, fewer morning erections, low energy, reduced vitality, low mood, and shifts in body composition. They support a diagnosis only when they persist and fit the laboratory picture.

Why “persistent” matters

Persistent means the problem remains present over time and is confirmed on repeat testing under the right conditions. Testosterone falls transiently during acute illness, after poor sleep, with calorie restriction, and under physiologic stress. If blood is drawn during that window, the result may reflect a temporary adaptive state rather than chronic hypogonadism.[2] [3]

That is why a single low result is only the start of the evaluation, and why fatigue by itself is not enough. In clinical terms, a syndrome is a recognizable combination of symptoms, signs, and objective findings that fit together.

Why guidelines and lab ranges disagree

Guidelines agree on the basics: persistent symptoms, an accurate assay, repeat morning testing, and free testosterone when total testosterone does not match the clinical picture.[1] [2] [3]

Where they differ is the numeric line. The AUA guideline treats total testosterone below 300 ng/dL as a reasonable cutoff in support of the diagnosis.[1] The 2018 Endocrine Society guideline points to the harmonized lower limit of 264 ng/dL derived from healthy young men.[2] [8] The EAU guideline uses about 12 nmol/L (roughly 350 ng/dL) for total testosterone and about 243 pmol/L (roughly 70 pg/mL) for free testosterone.[3]

Why the guidelines differ

The differences are mostly about where to draw the line and how much weight free testosterone receives. Free testosterone becomes especially important when SHBG is abnormal or when symptoms and total testosterone do not line up.[2] [4]

A man at 280 ng/dL on repeat morning testing falls below the AUA cutoff. A man at 320 ng/dL needs a fuller workup, not a reflex dismissal. If his symptoms persist and his free testosterone is low, testosterone deficiency may still be present.[1] [4]

Treating the lab result as an on or off switch is where many men fall through the cracks.

Why there is no sharp cutoff

There is no biologic cliff where a man is well at 351 ng/dL and hypogonadal at 349 ng/dL. Testosterone varies within the same man by time of day, sleep quality, acute illness, stress, and season. That is why borderline results should be repeated in the morning under stable conditions, especially in younger men, whose levels are highest early in the day.[2] [3]

Assay methodology adds another layer of noise. A substantial share of the variation in testosterone results between large cohort studies comes from assay differences.[8] Direct free testosterone immunoassays are particularly unreliable, giving values that are only a fraction of those obtained by equilibrium dialysis.[9] According to the Endocrine Society, clinicians should measure fasting morning total testosterone with an accurate and reliable assay.[2]

Population reference ranges also blur the picture. The harmonized range of 264 to 916 ng/dL comes from healthy nonobese men aged 19 to 39 in four US and European cohorts, with results calibrated to a CDC reference method.[8] It is a useful standard, but a single range cannot decide whether a particular man with persistent symptoms is deficient. Repeat morning testing and free testosterone still carry that weight. For a deeper explanation of why a report can look “normal” and still miss testosterone deficiency, see Why your testosterone test came back “normal” and why that might be wrong.

Why a “normal” test may still miss testosterone deficiency

Total testosterone alone can miss clinically relevant testosterone deficiency because only a small fraction of circulating testosterone is free and readily available to tissues.[9] [4]

Free testosterone is the unbound fraction that can readily enter tissues and activate androgen receptors. Bioavailable testosterone includes free testosterone plus the albumin bound fraction, which dissociates easily at the tissue level.

Total, free, and bioavailable testosterone

A 1981 study of steroid binding in human plasma estimated that in men about 2% of testosterone circulates free, about 44% is tightly bound to sex hormone binding globulin (SHBG), and about half is loosely bound to albumin.[5] When SHBG rises, the free fraction can fall even if total testosterone stays in the reference range.[4]

This is why a man can have a normal total testosterone on a routine report and still have real testosterone deficiency. Common reasons for higher SHBG include aging, liver disease, hyperthyroidism, and some medications. In that setting, total testosterone may overestimate what tissues can actually use.

A 2016 Journal of Clinical Endocrinology and Metabolism study of 3,334 men aged 40 to 79 found that men with normal total testosterone but low calculated free testosterone had higher SHBG and LH and reported more sexual and physical symptoms, while men with low total but normal free testosterone lacked features of androgen deficiency.[4]

A 1999 Journal of Clinical Endocrinology and Metabolism study by Vermeulen and colleagues found that free testosterone calculated from total testosterone and SHBG gave values almost identical to equilibrium dialysis, while direct analog immunoassays and the free androgen index were not reliable.[9] Equilibrium dialysis is the reference method, but it is time consuming and less widely available.[9] The Endocrine Society recommends obtaining free testosterone by equilibrium dialysis or an accurate formula when total testosterone is near the lower limit of normal or a condition alters SHBG.[2]

Why men with the same total testosterone feel different

Men with the same total testosterone can feel very different because testosterone action depends on more than the total concentration in blood. Tissue sensitivity and androgen receptor signaling vary, and SHBG changes free testosterone availability. Genetic variation, including androgen receptor CAG repeat length, may also alter how strongly a given testosterone level is felt at the tissue level, although evidence on how much this changes symptoms in routine practice is mixed and it does not replace symptom assessment, repeat morning testing, and accurate free testosterone measurement.

Clinically, this means two things. First, a man with persistent symptoms at 400 ng/dL should not be dismissed without looking at free testosterone and the broader endocrine picture. Second, a man with 350 ng/dL and no symptoms does not automatically have male hypogonadism. For age specific context, see Low testosterone by age: What’s normal at 20, 30, 40, 50, and beyond.

Where the problem starts

The origin of testosterone deficiency determines treatment, which is why LH and FSH must be measured alongside testosterone at the initial evaluation.[2] [3]

LH and FSH are pituitary hormones that signal the testes to make testosterone and support sperm production.

The hypothalamus and pituitary send signals through LH and FSH, the testes produce testosterone, and tissues respond to the hormone that is actually available to them.

The three broad categories

Hypogonadism can arise from three broad categories. Primary hypogonadism begins in the testes. Secondary hypogonadism begins in the hypothalamus or pituitary, which means the brain is not sending an adequate signal. Functional hypogonadism reflects potentially reversible suppression of the axis from factors such as obesity, sleep loss, systemic illness, medications, or metabolic stress. Rare conditions such as androgen resistance can also impair testosterone action, but they are not a core category in a routine low testosterone workup.

The same total testosterone result can therefore represent very different diseases. The man with testicular failure and the man with intact testes but poor pituitary signaling do not need the same treatment plan.

Why classification changes treatment

High LH plus low testosterone points to primary hypogonadism, where the brain is already signaling hard and the testes are not responding. Low or normal LH plus low testosterone points to secondary hypogonadism, where the testes may still work if the signal is restored.[2] [3]

This distinction determines whether a man likely needs testosterone replacement or may be able to restore natural production with stimulation therapy. Enclomiphene blocks estrogen receptors at the hypothalamus so the pituitary releases more LH, and the testes respond by making more testosterone without the suppression of sperm production that testosterone therapy causes. Testosterone therapy is not recommended for men planning fertility in the near term.[2] In primary hypogonadism, stimulating the axis will not fix testicular failure.

For a fuller explanation of classification, see Primary vs secondary hypogonadism: where the problem starts and why it changes everything. For the full diagnostic workflow, see The complete low testosterone testing guide.

A provider who skips LH and FSH is making a treatment decision without first defining the disease. That is how men are steered straight to testosterone when they may be candidates for fertility preserving stimulation therapy.

Which conditions cause hypogonadism?

Hypogonadism has named medical causes on both sides of the hormone axis, and the Endocrine Society guideline calls for a search for the cause once testosterone deficiency is confirmed.[2] The most common genetic cause of primary hypogonadism is Klinefelter syndrome, an extra X chromosome (47,XXY) that affects about one in 660 men and leaves the testes small and unable to make enough testosterone.[10] [11]

Most men with Klinefelter syndrome never learn they have it. A Danish national registry found that only about a quarter of affected adult men had been diagnosed, and the mean age at diagnosis is in the mid-30s.[10] [11]

On the secondary side, Kallmann syndrome is congenital hypogonadotropic hypogonadism, a failure of the brain hormone GnRH that drives the pituitary gland, combined with a reduced or absent sense of smell; about half of men with congenital hypogonadotropic hypogonadism have that smell defect.[12] Both conditions are rare next to the functional causes above, but they are the reason a low result with abnormal LH and FSH deserves a cause, not just a number.

What testosterone does across the body

Testosterone is a systemic hormone that affects muscle, bone, fat distribution, red blood cell production, sexual function, mood, cognition, and metabolic function.[2] [3]

Depending on the cause, conditions linked to testosterone deficiency can include sexual dysfunction, infertility, anemia, low bone density, increased fat mass, reduced lean mass, and underlying pituitary or testicular disorders.

According to the Endocrine Society guideline, testosterone deficiency is associated with reduced libido and sexual function, loss of body hair, low bone mineral density, anemia, decreased lean mass, increased fat mass, and reduced vitality.[2] The EAU guideline likewise describes late onset hypogonadism as a condition that combines low testosterone with symptoms of impaired hormone production or action.[3]

Why low testosterone is not just cosmetic

Testosterone helps maintain lean mass and supports normal fat distribution, which is why deficiency often shifts body composition toward more central fat and less muscle. It also supports bone remodeling, and severe or prolonged deficiency can contribute to bone loss. Testosterone stimulates erythropoiesis, which is red blood cell production, so deficiency can contribute to lower hemoglobin in some men.[2]

Its effects on mood, cognition, and metabolic health are less clear but still clinically relevant. Men with hypogonadism often report lower energy, reduced motivation, and worse overall well being. Low testosterone is also associated with cardiometabolic disease, although association does not prove that low testosterone is the cause. Testosterone deficiency is a multisystem clinical condition, not a cosmetic complaint about “optimization.”

Myth vs fact

Myth: A low lab number alone means you have low T

Fact: Male hypogonadism requires both persistent symptoms and biochemical evidence. A low number without symptoms is not sufficient for diagnosis.[2] [3]

Myth: If your total testosterone is above the lab’s lower limit, low testosterone is ruled out

Fact: Diagnosis depends on persistent symptoms, repeat morning testing, and free testosterone when appropriate. Men with normal total testosterone but low free testosterone report more sexual and physical symptoms of androgen deficiency.[2] [4]

Myth: Total testosterone is all that matters

Fact: Only about 2% of testosterone is free, and elevated SHBG can lower free testosterone even when total testosterone looks acceptable. Free testosterone can uncover hidden testosterone deficiency.[5] [4]

Myth: Treatment choice is the same no matter where the problem starts

Fact: The source of the problem changes treatment. High LH plus low testosterone suggests primary hypogonadism, while low or normal LH plus low testosterone suggests secondary hypogonadism.[2] [3] In secondary hypogonadism the testes can still respond, so restoring the brain’s signal with enclomiphene may raise natural production while preserving fertility.

In practice, the next steps are to repeat morning testing, measure LH and FSH, check free testosterone when appropriate, look for reversible causes, and base treatment on whether the problem is primary, secondary, or functional.

Bottom line

Low testosterone is not simply a low lab number. It is male hypogonadism, a clinical syndrome that requires persistent symptoms, accurate morning hormone testing, and biochemical testosterone deficiency interpreted in context. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have. Licensed providers follow Veedma’s protocol, which considers treatment when symptoms persist and free testosterone is below 100 pg/mL, using enclomiphene or the enclomiphene plus tadalafil tablet when appropriate. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
  2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  3. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
  4. Antonio L, Wu FC, O’Neill TW, et al. Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab. 2016;101:2647-57. PMID: 26909800
  5. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68. PMID: 7195404
  6. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-59. PMID: 20525905
  7. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35. PMID: 20554979
  8. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102:1161-1173. PMID: 28324103
  9. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-72. PMID: 10523012
  10. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88:622-6. PMID: 12574191
  11. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome–a clinical update. J Clin Endocrinol Metab. 2013;98:20-30. PMID: 23118429
  12. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism–pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547-64. PMID: 26194704

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.